'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer - PubMed (original) (raw)

'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

A G Pallis et al. Br J Cancer. 2007.

Abstract

'Classical' mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC. The aim of the current study was to evaluate whether other than the classical G719X, DEL19 and L858R mutations of EGFR confer sensitivity to TKIs. Genomic DNA was extracted from microdissected formalin-fixed paraffin-embedded tumour tissue from 86 patients treated with gefitinib. Exons 18, 19 and 21 were amplified and subjected to direct sequencing. Eleven (13%) patients harboured the classical exon's 18, 19 and 21 mutations, while 14 (16%) had 'other' variants. There was a significantly higher percentage of 'never-smoker' patients with 'classical' EGFR mutations (P=0.002). Among patients with 'classical' mutations 3 patients achieved PR and 7 SD, while in the 'other' mutations group 10 patients had SD as best response. In the wild-type group, there were 3 patients with PR and 25 with SD. Median TTP was 16, 64 (P=0.002) and 21 weeks and median survival was 36, 78 and 67 weeks for patients with wild-type, 'classical' and 'other' EGFR mutations, respectively. The clinical relevance of 'other' EGFR mutation variants remains uncertain and requires further assessment in a prospective study.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Kaplan–Meier curve of time to tumour progression (TTP) of wild-type EGFR patients group, ‘classical’ and ‘other’ mutations group. *_P_-value between ‘classical’ and wild type.

Figure 2

Figure 2

Kaplan–Meier survival curve of wild-type EGFR patients group, ‘classical’ and ‘other’ mutations group.

Figure 3

Figure 3

Kaplan–Meier survival curve of patients with the ‘classical’ DEL19 mutation and wild-type EGFR.

Similar articles

Cited by

References

    1. Altman GD (1991) Practical Statistics for Medical Research. London, UK: Chapman and Hall
    1. Argiris A, Mittal N, Masters G (2003) Gefitinib (ZD1839) as first line, compassionate use therapy in patients with advanced NSCLC. Proc Am Soc Clin Oncol 22; Abstract 2729
    1. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081–8092 - PubMed
    1. Calvo E, Baselga J (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24: 2158–2163 - PubMed
    1. Carney DN (2002) Lung cancer – time to move on from chemotherapy. N Engl J Med 346: 126–128 - PubMed

MeSH terms

Substances

LinkOut - more resources